PIVOTAL is an open label, randomized, multicenter, Phase III trial evaluating Nidlegy as a neoadjuvant intralesional therapy
Advancing IGC-AD1 Toward Commercialization as a Treatment for Agitation in Alzheimer's
For use with Hamamatsu Images acquired with the NanoZoomer S360MD slide scanner
Operationally ready by 2029, it will be the Company’s first-ever facility to cover the full manufacturing process for ADCs
95.7% of patients responded to Breyanzi in the TRANSCEND FL trial
Pivotal OASIS 1 and 2 Phase III studies of investigational compound elinzanetant achieved a statistically significant reduction in frequency and severity of vasomotor symptoms
Outlook 2024 remains flat CER sales growth and CORE EBITDA margin of high 20s
EBITDA before special items falls 1.3 percent to € 4.41 billion
the campaign emphasizes the brand's reliability and effectiveness in providing timely relief
TIVDAK is the first antibody-drug conjugate (ADC) to have positive overall survival data for patients with previously treated recurrent or metastatic cervical cancer
Subscribe To Our Newsletter & Stay Updated
